Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 846 GBX -0.47%
Market Cap: £1B

Operating Margin

-20.3%
Current
Improving
by 33.5%
vs 3-y average of -53.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-20.3%
=
Operating Income
£-30.7m
/
Revenue
£151.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-20.3%
=
Operating Income
GBX-30.7m
/
Revenue
£151.2m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Oxford BioMedica PLC
LSE:OXB
1B GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in United Kingdom
Percentile
5th
Based on 3 579 companies
5th percentile
-20.3%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Oxford BioMedica PLC
Glance View

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-20.3%
=
Operating Income
£-30.7m
/
Revenue
£151.2m
What is Oxford BioMedica PLC's current Operating Margin?

The current Operating Margin for Oxford BioMedica PLC is -20.3%, which is above its 3-year median of -53.8%.

How has Operating Margin changed over time?

Over the last 3 years, Oxford BioMedica PLC’s Operating Margin has decreased from -14.2% to -20.3%. During this period, it reached a low of -96% on Dec 31, 2023 and a high of -14.2% on May 30, 2022.

Back to Top